The market may believe the company's recent revenue performance is insufficient compared to the industry, given its low P/S ratio. Without top-line growth improvement, the ratio could fall further. Given recent revenue trends, significant share price movement seems unlikely soon.
瑞康醫葯股票討論區
暫無評論